AbCellera Biologics Inc (ABCL, Financial) is set to release its Q1 2025 earnings on May 8, 2025. The consensus estimate for Q1 2025 revenue is $7.53 million, and the earnings are expected to come in at -$0.14 per share. The full year 2025's revenue is expected to be $27.62 million and the earnings are expected to be -$0.62 per share. More detailed estimate data can be found on the Forecast page.
AbCellera Biologics Inc (ABCL, Financial) Estimates Trends
Over the past 90 days, revenue estimates for AbCellera Biologics Inc (ABCL) have declined from $43.35 million to $27.62 million for the full year 2025. Similarly, for 2026, revenue estimates have decreased from $64.93 million to $37.73 million. In terms of earnings, estimates have improved for the full year 2025, increasing from -$0.70 per share to -$0.62 per share. However, for 2026, earnings estimates have declined from -$0.58 per share to -$0.65 per share.
AbCellera Biologics Inc (ABCL, Financial) Reported History
In the previous quarter ending December 31, 2024, AbCellera Biologics Inc's (ABCL) actual revenue was $5.05 million, which missed analysts' revenue expectations of $7.58 million by -33.38%. AbCellera Biologics Inc's (ABCL) actual earnings were -$0.11 per share, which beat analysts' earnings expectations of -$0.148 per share by 25.68%. After releasing the results, AbCellera Biologics Inc (ABCL) was down by -11.47% in one day.
AbCellera Biologics Inc (ABCL, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 7 analysts, the average target price for AbCellera Biologics Inc (ABCL) is $12 with a high estimate of $28 and a low estimate of $5. The average target implies an upside of 491.13% from the current price of $2.03.
Based on GuruFocus estimates, the estimated GF Value for AbCellera Biologics Inc (ABCL, Financial) in one year is $1.23, suggesting a downside of -39.41% from the current price of $2.03.
Based on the consensus recommendation from 9 brokerage firms, AbCellera Biologics Inc's (ABCL, Financial) average brokerage recommendation is currently 1.9, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
